Allegheny Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Allegheny Financial Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.2K	Hold	20,000	–	–	﹤0.01%	304
2026 Q1	$31.6K	Hold	20,000	–	–	﹤0.01%	289
2025 Q4	$33.4K	Hold	20,000	–	–	﹤0.01%	285
2025 Q3	$33.8K	Hold	20,000	–	–	0.01%	262
2025 Q2	$18.1K	Hold	20,000	–	–	﹤0.01%	247
2025 Q1	$9.03K	Hold	20,000	–	–	﹤0.01%	230
2024 Q4	$10.1K	Hold	20,000	–	–	﹤0.01%	229
2024 Q3	$18.1K	Hold	20,000	–	–	﹤0.01%	240
2024 Q2	$19.9K	Hold	20,000	–	–	0.01%	219
2024 Q1	$29.6K	Hold	20,000	–	–	0.01%	203
2023 Q4	$21.8K	Hold	20,000	–	–	0.01%	208
2023 Q3	$23.6K	Buy	+20,000	New	+$27.2K	0.01%	190
2023 Q2	–	Sell	-20,000	Closed	-$30K	–	157
2023 Q1	$30K	Hold	20,000	–	–	0.01%	161
2022 Q4	$23.4K	Hold	20,000	–	–	0.01%	165
2022 Q3	$22K	Hold	20,000	–	–	0.01%	156
2022 Q2	$32K	Hold	20,000	–	–	0.01%	163
2022 Q1	$31K	Hold	20,000	–	–	0.01%	159
2021 Q4	$49K	Hold	20,000	–	–	0.02%	156
2021 Q3	$50K	Hold	20,000	–	–	0.02%	150
2021 Q2	$57K	Hold	20,000	–	–	0.03%	152
2021 Q1	$47K	Hold	20,000	–	–	0.03%	101
2020 Q4	$35K	Buy	+20,000	New	+$28K	0.02%	130

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Allegheny Financial Group's LCTX Position: Q2 2026 in Review

Allegheny Financial Group held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 20,000 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #304.

Allegheny Financial Group first reported a position in LCTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $57K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Allegheny Financial Group held 20,000 shares of Lineage Cell Therapeutics worth $26.2K as of Q2 2026.
Allegheny Financial Group left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Allegheny Financial Group's portfolio in Q2 2026, its #304 holding.
Allegheny Financial Group first reported a position in Lineage Cell Therapeutics in Q4 2020 and has held it in 22 quarters since.
Allegheny Financial Group's Lineage Cell Therapeutics position peaked at $57K in Q2 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Allegheny Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.